SELLAS Life Sciences (NASDAQ:SLS) rises as short interest builds, company files change-control ahead of AML update
SELLAS Life Sciences jumped 6.3% to $11.19 after amending executive severance terms, with short interest at 32.65% of float and trading volume doubling the average; the stock’s market value far exceeds cash on hand, and investors await final Phase 3 AML trial results with 78 of 80 events reached.